PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Perioperative Pembrolizumab in Resectable HNSCC: Ten-Year Evidence Review

pembrolizumabnivolumabipilimumabavelumabcamrelizumabPD-1 inhibitorPD-L1immune checkpoint inhibitorhead and neck squamous cell carcinomaperioperative immunotherapyneoadjuvantKEYNOTE-689narrative reviewevent-free survivalCPSoncology pharmacy Oncology

Background Information

Pembrolizumab shows promise in perioperative treatment of resectable HNSCC.

Perioperative immune checkpoint inhibitors may improve outcomes in head and neck squamous cell carcinoma (HNSCC). The KEYNOTE-689 trial showed improved event-free survival with perioperative pembrolizumab in HNSCC patients with PD-L1 combined positive score (CPS) ≥1. While pembrolizumab is beneficial in specific HNSCC patients, optimal perioperative regimens and guidelines are still emerging. Pembrolizumab in perioperative settings shows promise for certain HNSCC patients, backed by KEYNOTE-689.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Freeman H, Rawson C, Al-Saidi N, Lucke-Wold B, Karsy M, Pahlevani M

Citation: Freeman H, Rawson C, Al-Saidi N, et al. Perioperative immune checkpoint inhibition in head and neck squamous cell carcinoma: a 10-year review. Exploration of targeted anti-tumor therapy. 2026;7:1002406. doi:10.37349/etat.2026.1002406

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.